FDA Expands Approval of Roflumilast Foam for Treating Scalp, Body Psoriasis

FDA Expands Approval of Roflumilast Foam for Treating Scalp, Body Psoriasis

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older. Medscape Medical News

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

The foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast has been approved by the US Food and Drug Administration (FDA) for treating plaque psoriasis of the scalp and body in adults and adolescents aged 12 years and older, according to an announcement from the manufacturer Arcutis Biotherapeutics. The 0.3% foam formulation of roflumilast (Zoryve) was […] The post FDA Approves Roflumilast Foam for Scalp, Body Psoriasis first a…

FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body

The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis

Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.

FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.